Good afternoon :)
$
₹
Legend Biotech Corp

Legend Biotech Corp

LEGN

NASDAQ
Asset Logo

Legend Biotech Corp

LEGN

NASDAQ
$17.600.16% (+0.02)
$
₹
$17.600.16% (+0.02)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Mid Cap

With a market cap of $3.3B the stock is ranked 1789

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

2.79
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.48
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-7.19%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 22 analysts' reports

Buy
21 analysts
Hold
1 analyst
Sell
0 analyst

Analysts expect a +175.29% price upside over the next year

Current Price$17.60
Target Price$48.47

Company Profile

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.

Peers

Peers

AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
74.15
74.15
1Y Return
19.79%
19.79%
Buy Reco %
57.14
57.14
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
23.30
23.30
1Y Return
38.66%
38.66%
Buy Reco %
46.87
46.87
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
32.8%
32.8%
Buy Reco %
63.33
63.33
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
29.94
29.94
1Y Return
31.31%
31.31%
Buy Reco %
52.94
52.94
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
19.15
19.15
1Y Return
31.25%
31.25%
Buy Reco %
76.00
76.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Legend Biotech Corp -2.79-
AbbVie Inc74.1550.450.53
Amgen Inc23.3017.372.26

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

272.3
-39.6
306.3
-30.8
305.1
-54.3
387.5
33.2
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue93.99186.52160.20186.52195.05255.05272.33306.37305.1387.5
Net Income-59.79-18.19-125.3226.28-100.91-125.38-39.68-30.81-54.333.2
Net Profit Margin-63.61%-9.75%-78.22%14.09%-51.73%-49.15%-14.57%-10.05%-17.79%8.56%
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. Legend Biotech Corp (LEGN) share price today is $17.60 as of September 19, 2026 at 1:30 AM IST. The stock touched a day high of $17.85 and a day low of $17.22.

  2. Legend Biotech Corp stock trades on NASDAQ under the ticker symbol LEGN.

  3. Legend Biotech Corp's market capitalization is $3.3B as of September 19, 2026 at 1:30 AM IST.

  4. Legend Biotech Corp's price-to-earnings (P/E) ratio is N/A as of September 18, 2026.

  5. Legend Biotech Corp's price-to-book (P/B) ratio is 2.79 as of September 18, 2026.

  6. Yes, You can buy Legend Biotech Corp shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Legend Biotech Corp shares in three steps: 1. Search Legend Biotech Corp on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Legend Biotech Corp trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Legend Biotech Corp (LEGN) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.5678 shares at the current price of $17.60.

Loading...